Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3971355rdf:typepubmed:Citationlld:pubmed
pubmed-article:3971355lifeskim:mentionsumls-concept:C0034715lld:lifeskim
pubmed-article:3971355lifeskim:mentionsumls-concept:C0023903lld:lifeskim
pubmed-article:3971355lifeskim:mentionsumls-concept:C0001563lld:lifeskim
pubmed-article:3971355lifeskim:mentionsumls-concept:C0178602lld:lifeskim
pubmed-article:3971355lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:3971355lifeskim:mentionsumls-concept:C0027253lld:lifeskim
pubmed-article:3971355lifeskim:mentionsumls-concept:C0205267lld:lifeskim
pubmed-article:3971355lifeskim:mentionsumls-concept:C0439603lld:lifeskim
pubmed-article:3971355pubmed:issue1lld:pubmed
pubmed-article:3971355pubmed:dateCreated1985-4-17lld:pubmed
pubmed-article:3971355pubmed:abstractTextN-Nitrosopyrrolidine (N-Pyr) was administered orally to 400 Sprague-Dawley rats. An additional group of 80 rats served as an untreated control. There were 5 individual groups in which the effects of different periods of dosing and varying intervals without treatment were compared. Individual doses corresponded to 0.0, 1.0, 1.2 and 2.0 mg/kg per day. The total dose (600 days after the start of the trial) always amounted to 600 mg/kg N-Pyr. Significantly different incidences of liver tumors were observed in the individual N-Pyr-treated groups. The findings support the assumption that tumor risks not only depend on individual and total doses of the administered carcinogen, but are also an age-related function.lld:pubmed
pubmed-article:3971355pubmed:languageenglld:pubmed
pubmed-article:3971355pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3971355pubmed:citationSubsetIMlld:pubmed
pubmed-article:3971355pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3971355pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3971355pubmed:statusMEDLINElld:pubmed
pubmed-article:3971355pubmed:monthFeblld:pubmed
pubmed-article:3971355pubmed:issn0304-3835lld:pubmed
pubmed-article:3971355pubmed:authorpubmed-author:SchmählDDlld:pubmed
pubmed-article:3971355pubmed:authorpubmed-author:HabsMMlld:pubmed
pubmed-article:3971355pubmed:authorpubmed-author:HoopBBlld:pubmed
pubmed-article:3971355pubmed:issnTypePrintlld:pubmed
pubmed-article:3971355pubmed:volume26lld:pubmed
pubmed-article:3971355pubmed:ownerNLMlld:pubmed
pubmed-article:3971355pubmed:authorsCompleteYlld:pubmed
pubmed-article:3971355pubmed:pagination77-82lld:pubmed
pubmed-article:3971355pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3971355pubmed:meshHeadingpubmed-meshheading:3971355-...lld:pubmed
pubmed-article:3971355pubmed:meshHeadingpubmed-meshheading:3971355-...lld:pubmed
pubmed-article:3971355pubmed:meshHeadingpubmed-meshheading:3971355-...lld:pubmed
pubmed-article:3971355pubmed:meshHeadingpubmed-meshheading:3971355-...lld:pubmed
pubmed-article:3971355pubmed:meshHeadingpubmed-meshheading:3971355-...lld:pubmed
pubmed-article:3971355pubmed:meshHeadingpubmed-meshheading:3971355-...lld:pubmed
pubmed-article:3971355pubmed:meshHeadingpubmed-meshheading:3971355-...lld:pubmed
pubmed-article:3971355pubmed:meshHeadingpubmed-meshheading:3971355-...lld:pubmed
pubmed-article:3971355pubmed:meshHeadingpubmed-meshheading:3971355-...lld:pubmed
pubmed-article:3971355pubmed:meshHeadingpubmed-meshheading:3971355-...lld:pubmed
pubmed-article:3971355pubmed:year1985lld:pubmed
pubmed-article:3971355pubmed:articleTitleComparison of liver tumor frequencies after intermittent oral administration of different doses of N-nitrosopyrrolidine in Sprague-Dawley rats.lld:pubmed
pubmed-article:3971355pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3971355pubmed:publicationTypeComparative Studylld:pubmed